fenamic acid

Fenamic acid (N-Phenylanthranilic acid) is a chloride channel blocker that causes renal papillary necrosis in rats. Fenamic acid serves as a parent structure for several nonsteroidal anti-inflammatory drugs (NSAIDs), including flufenamic acid, tolfenamic acid, mefenamic acid, and meclofenamic acid.

Tolfenamic Acid (GEA 6414) is a non-steroidal anti-inflammatory drug (NSAID) used to treat migraine symptoms.

Flufenamic acid (Arlef) is an anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

Mefenamic acid (CN-35355) is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Clofenamic acid ,with CAS No. 13278-36-9, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Clofenamic acid provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Meclofenamic acid sodium (Movens), a non-steroidal anti-inflammatory agent, has properties of antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.

Meclofenamic acid (Meclofenamate) is a non-selective gap-junction blocker and a selective inhibitor of the fat mass and obesity-associated (FTO) enzyme, with notable anti-inflammatory activities.

Flufenamic Acid-D4 is intended for use as an internal standard for the quantification of flufenamic acid by GC- or LC-MS. Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 3 and 9.3 µM for human COX-1 and COX-2, respectively). Flufenamic acid inhibits TNF-α-induced increases in COX-2 levels and NF-κB activation in HT-29 colon cancer cells in a concentration-dependent manner. It inhibits calcium influx induced by fMLP or A23187 in human polymorphonuclear leukocytes (PMN) with IC50 values of 29 and 14 µM, respectively. Flufenamic acid also activates various ion channels, including transient receptor potential canonical 6 (TRPC6) and the large-conductance calcium-activated potassium channel (KCa1.1). It also inhibits various ion channels, including TRPC3 and the cystic fibrosis transmembrane conductance regulator (CFTR). Flufenamic acid (20 mg/kg) reduces increases in intestinal fluid secretion and intestinal barrier disruption in mice ......

Enfenamic acid is a platelet aggregation inhibitor and with antirheumatic.

MefenaMic Acid-D4 is a deuterated compound of MefenaMic Acid. MefenaMic Acid (T0890) has a CAS number of 61-68-7. Mefenamic acid is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Mefenamic acid (Standard) is the standard substance of Mefenamic acid, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Mefenamic acid (CN-35355) is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Tolfenamic acid (Standard) is the standard substance of Tolfenamic acid, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Tolfenamic Acid (GEA 6414) is one of the class of non-steroidal anti-inflammatory drugs (NSAIDs). It is used to treat the symptoms of migraine.

Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug developed for the treatment of skin diseases.

ABC294640, also known as Opaganib, is an orally available, aryladamantane compound and selective inhibitor of sphingosine kinase-2 (SK2) with potential antineoplastic activity. Upon administration, ABC294640 competitively binds to and inhibits SK2, thereby preventing the phosphorylation of the pro-apoptotic amino alcohol sphingosine to sphingosine 1-phosphate (S1P), the lipid mediator that is pro-survival and critical for immunomodulation. This may eventually lead to the induction of apoptosis and may result in an inhibition of cell proliferation in cancer cells overexpressing SK2.